These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 26709138)
21. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Yan J; Xie B; Capodice JL; Katz AE Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835 [TBL] [Abstract][Full Text] [Related]
22. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401 [TBL] [Abstract][Full Text] [Related]
23. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog. Berkovich L; Ben-Shabat S; Sintov AC Anticancer Drugs; 2010 Jul; 21(6):609-18. PubMed ID: 20335794 [TBL] [Abstract][Full Text] [Related]
24. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Sepulveda VA; Weigel NL; Falzon M Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370 [TBL] [Abstract][Full Text] [Related]
25. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Skowronski RJ; Peehl DM; Feldman D Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193 [TBL] [Abstract][Full Text] [Related]
26. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Ly LH; Zhao XY; Holloway L; Feldman D Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956 [TBL] [Abstract][Full Text] [Related]
27. Red Maca (Lepidium meyenii) did not affect cell viability despite increased androgen receptor and prostate-specific antigen gene expression in the human prostate cancer cell line LNCaP. Díaz P; Cardenas H; Orihuela PA Andrologia; 2016 Oct; 48(8):922-6. PubMed ID: 27681649 [TBL] [Abstract][Full Text] [Related]
28. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934 [TBL] [Abstract][Full Text] [Related]
29. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Muindi JR; Yu WD; Ma Y; Engler KL; Kong RX; Trump DL; Johnson CS Endocrinology; 2010 Sep; 151(9):4301-12. PubMed ID: 20591973 [TBL] [Abstract][Full Text] [Related]
30. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells. Yu Y; Zhou Q; Hang Y; Bu X; Jia W Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948 [TBL] [Abstract][Full Text] [Related]
31. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer. Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160 [TBL] [Abstract][Full Text] [Related]
33. 7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells. Díaz-Carballo D; Gustmann S; Acikelli AH; Bardenheuer W; Buehler H; Jastrow H; Ergun S; Strumberg D Phytomedicine; 2012 Nov; 19(14):1298-306. PubMed ID: 22981203 [TBL] [Abstract][Full Text] [Related]
34. Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells. Lee LR; Teng PN; Nguyen H; Hood BL; Kavandi L; Wang G; Turbov JM; Thaete LG; Hamilton CA; Maxwell GL; Rodriguez GC; Conrads TP; Syed V Cancer Prev Res (Phila); 2013 Jul; 6(7):731-43. PubMed ID: 23682076 [TBL] [Abstract][Full Text] [Related]
35. 1,25-Dihydroxyvitamin D Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245 [TBL] [Abstract][Full Text] [Related]
36. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells. Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521 [TBL] [Abstract][Full Text] [Related]
37. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900 [TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635 [TBL] [Abstract][Full Text] [Related]
39. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097 [TBL] [Abstract][Full Text] [Related]
40. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Zhuang SH; Schwartz GG; Cameron D; Burnstein KL Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]